Eli Lilly (LLY) stock rose slightly early Thursday after the drug giant reported adjusted earnings of $5.32 per share on $13.53 billion in fourth-quarter sales.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?On average, analysts polled by FactSet expected Lilly to earn $5.06 per share and report $13.55 billion in sales. In the year-earlier period, the pharma company reported earnings of $2.49 per share on $9.35 billion in sales.
Weight-loss drug Zepbound generated $1.91 billion, while diabetes treatment Mounjaro brought in $3.53 billion. Analysts called for a respective $1.99 billion and $3.63 billion in sales.
For the year, Eli Lilly guided to adjusted EPS of $22.50-$24 on revenue of $58 billion-$61 billion, with the midpoints both above consensus. The Street called for adjusted earnings of $22.76 per share and $58.77 billion in sales.
In premarket trades on the stock market today, Eli Lilly stock rose 1.2%. Shares are consolidating with a buy point at 972.53, according to MarketSurge. On Wednesday, LLY stock closed above its 200-day line for the first time in nearly three months.
More to follow.
YOU MAY ALSO LIKE:
Novo Surges As Ozempic Drives Fourth-Quarter Beat. But Supply Shortages Expected.
How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。